top of page
2026 POSTER ABSTRACTS
Abstract #
Abstract Title
POSTER SESSION 1: October 28 4:30-6:30 PM ET
The Gupta Family Endowed Prize for Innovation in ALS Care | |
Drs. Ayeez and Shelena Lalji & Family Student Scholar Award for
Repair and Regenerative Mechanisms in ALS | |
1 | An Astrocyte Signature That Replicated Across Three ALS Cohorts and Still Was Not Real: The Case for Out-of-Sample Validation |
2 | NU-9 Treatment in Three Different ALS Models Validate Mitochondrial Integrity Restoration, Introducing Circulating cf-mtDNA as a Potential Target Engagement Biomarker |
3 | Exosome Proteomics of Serum from Patients with SOD1D90A Mutation and at Different Stages of their Disease Reveal Changes in Disease Mechanisms, and potential biomarkers |
4 | Toward trustworthy remote speech biomarkers in ALS: modeling recording quality as a multidimensional measurement property |
5 | Objective muscle strength (NOVA-IMS): a prespecifiable, outcome-independent stratifier of progression rate for ALS trials with ALSFRS-R as the primary outcome |
6 | Baseline Biomarker Predictors of Neurofilament Light Chain Response to Oral Fasudil in ALS: An Exploratory Analysis from the REAL Phase 2 Study |
7 | Mitigating Clinical Heterogeneity in ALS Trials: The Biological Rationale and Statistical Impact of 3-Tiered Neurofilament Light (NfL) Stratification in the ALSTARS Trial |
8 | On-Treatment NfL Response Identifies a Two-Year Survival Difference in RESCUE-ALS and Replicates Across Two Independent CNM-Au8 Trials |
9 | Treatment Benefit of CNM-Au8 in the HEALEY ALS Platform Trial Is Concentrated in Participants with On-Treatment NfL Decline or Stabilization: Concordance and Randomization-Anchored Causal Analyses |
10 | Metabolomics and Lipidomics Signatures and Machine Learning Algorithms to Differentiate ALS and PLS |
11 | ALSmiR: A curated community resource for ALS MicroRNA biomarker discovery |
12 | ERACE (Emory Rapid Access Clinical Evaluation) 10-protein model predicts ALS from plasma with high accuracy |
13 | Serum Neurofilament Light Chain characterization using data collected from the HEALEY ALS Platform Trial |
14 | Longitudinal Neurofilament Light Chain Trajectory Is Associated with Survival in ALS: Prespecified Analyses Across Two Independent Cohorts |
15 | Retinal OCT and OCTA Biomarker Readiness in Amyotrophic Lateral Sclerosis: A Systematic Review of Longitudinal Evidence, Disease-Stage Effects, and Methodological Quality |
17 | Preliminary Support for a Divergence Between Central and Peripheral Motor Excitability in ALS |
18 | Network of Excellence for Amyotrophic Lateral Sclerosis (NEALS) Biorepository |
19 | Utilization of Wrist-Worn Actigraphy to Evaluate Patient-Reported Fatigue and Sleep in a Pilot ALS Cohort |
21 | Free-Living Ambulation Tracking in ALS Using Wearable Sensors |
22 | Remotely collected wearable digital data can detect development of comorbid disease in ALS. |
23 | Plasma tau phosphorylated at T181 is elevated in amyotrophic lateral sclerosis |
24 | Evaluation of Oculomotor Function for Monitoring Disease Progression in Amyotrophic Lateral Sclerosis |
25 | Designing ALS Trials using Serum Neurofilament Light Chain as an efficacy outcome: Operational Evidence from the HEALEY ALS Platform Trial |
26 | Plasma and CSF Biomarkers to Predict ALS Disease Progression |
27 | Quantitative ALS: Preliminary Validation of a Novel ALS Outcome Measure |
28 | Vimentin (VIM) Cryptic Exons as a Blood Biomarker of ALS |
29 | Characterizing microbial markers predictive for ALS onset and progression |
30 | The Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) Program: Building a Collaborative Framework for Biomarker and Therapeutic Advancement |
31 | Evaluation of consistency of Olink HT proteomics in ALS biofluids |
32 | Digital Split-Hand Index: Pilot Study of A Smartphone-Based Biomarker for Detecting Selective Motor Vulnerability in ALS |
33 | iBrain™ as a Remote Monitor of EEG and Sleep Activity in Amyotrophic Lateral Sclerosis |
34 | The Effect of Edaravone on CSHE in ALS and the Utility of SICI as a Pharmacodynamic Biomarker |
35 | From etiology to therapeutics of Lou Gehrig’s disease |
36 | DPTX3230 Restores TDP-43 Nuclear Function Across Translational Models of ALS |
37 | IKZF1 Links Peripheral Myeloid and Microglial Dysregulation in ALS: Concordant, Out-of-Sample Validation Across Six Single-Cell Cohorts |
38 | Presence of Somatic Mutations in sporadic ALS |
39 | Prevention of Unc13a cryptic splicing is sufficient to preserve memory |
40 | RNA processing dysregulation and fusion transcript formation in ALS |
41 | IPL344: DNA-damage-response-driven neuro-regeneration in ALS |
42 | Preclinical development of antisense oligonucleotide TRCN-1023 to restore UNC13A function in people living with Amyotrophic Lateral Sclerosis |
43 | Molecular Vulnerability of Upper Motor Neurons Despite Preserved Neuronal Composition in the ALS Motor Cortex |
44 | Epigenetic regulation of upper motor neuron vulnerability within the context of TDP-43 pathology |
45 | Proteomic Analyses Begin to Reveal Target Engagement and Efficacy of NU-9 in a Model of Misfolded SOD1 Toxicity |
46 | A High-Density Microelectrode Array Reveals That Corticospinal Motor Neurons With TDP-43 Pathology Are Prone To Hyperexcitation At Birth |
48 | RKER-065, an Activin/Myostatin Ligand Trap, Mitigated Disease Progression and Improved Muscle Function in an Amyotrophic Lateral Sclerosis Mouse Model |
49 | Treatment With a Stable GDNF Variant Improved Clinical Outcomes in a Mouse Model of Amyotrophic Lateral Sclerosis |
50 | RKER-065 preserved bone structure and function during disease progression in the SOD1-G93A mouse model of ALS |
51 | Shared targets and binding-site enrichment implicate RBFOX2 as a co-regulator of TDP-43-responsive splicing in human neurons |
52 | Bypassing the Blood-Brain Barrier: Systemic Delivery of SYT2-Targeted siSOD1 to Lower Motor Neurons Attenuates Motor Decline in SOD1-G93A Mice |
53 | The Development and Optimization of AAV-mediated Gene Medicine as Potential ALS Therapeutics |
54 | Injury-induced local axonal translation of importin-β1 supports motor axon regeneration and is disrupted by dipeptide repeat proteins in C9orf72 ALS |
55 | Prodromal Gene Expression Changes in the Spinal Cord of a Large Animal Model of Motor Neuron Degeneration |
56 | Preclinical characterization of prosetin, a novel, CNS-penetrant MAP4K inhibitor developed for the treatment of ALS |
57 | Impact of INS1202 AAV9-SOD1-shRNA Gene Therapy on Motor Neuron Survival and Hallmarks of Neurodegeneration in a Sporadic ALS Patient-Derived In Vitro Model |
60 | Performance of Quantitative Speech Metrics as Longitudinal Progression Markers in ALS |
61 | Baseline Enrichment to Increase Statistical Power of Quantitative Speech Metrics as Secondary Endpoints in ALS Clinical Trials |
62 | Caregiver-Supported Oral Hygiene Protocol in ALS: A Randomized Crossover Pilot Study |
63 | Spontaneous tonic chin dimpling associated with corticobulbar involvement in ALS |
64 | Speech-Language Pathology-Led Communication Planning for Gastrostomy in ALS/MND: Integration of Serious Illness Communication Principles and Anticipatory AAC Supports |
65 | Anticipating Feeding Tube Placement in ALS: Milestone Clustering and Baseline Predictors of Timing |
66 | A Proactive, Multisystem, Tiered Framework for Communication Management in ALS |
67 | Preliminary Evidence of a Short-Form Swallowing Quality of Life Measure in ALS |
68 | Effects of Combined Lung Volume Recruitment and Expiratory Strength Training on Pulmonary and Cough Function in People Living with ALS |
69 | Speech-Language Pathologists’ Knowledge and Clinical Confidence Following a Dysphagia Masterclass on MND/ALS Management |
70 | Texture Classification and Oral Processing of Commercially Available Protein Bars: Preliminary IDDSI Reference Data Relevant to Dysphagia and Nutritional Management |
71 | Differentiating Spinal- and Bulbar-Onset ALS: A Comparative Analysis of Remote Digital Speech Metrics and Spirometry |
72 | Psychological symptoms and swallowing difficulty in ALS: An exploratory pilot survey study |
73 | Associations of Bulbar Impairments with Social Connection in ALS: Preliminary Findings |
74 | Subclinical changes in speech metrics in individuals with spinal-onset ALS |
75 | Composite Speech Biomarkers for ALS: Reliability, Measurement Error, and Generalization from Natural History to Clinical Trial |
76 | Implementation of ALS Genetic Testing Guidelines: Uptake, Impact, and Opportunities at a Single ALS Center |
77 | Genetic Counseling and Testing Utilization in Individuals At-Risk for ALS/FTD Spectrum Disorders |
78 | Amyotrophic Lateral Sclerosis Genetic profile among cases reported in the CELA-PR Registry |
79 | Insights from sponsored genetic testing in patients with amyotrophic lateral sclerosis: A single-site retrospective study |
80 | Implementation of an ALS Prevention Continuum for Individuals at Genetic Risk of Amyotrophic Lateral Sclerosis |
81 | Examining the Clinical and Genetic Spectrum of TARDBP-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia |
82 | Motor neuron disease associated with biallelic repeat expansions in RFC1 |
83 | Assessing penetrance in genetic ALS: Implications for genetic counseling and predictive testing |
84 | Taskforce on Genetic Counselling and Testing in ALS/MND: Developing Global Consensus-Based Guidelines |
85 | PREVENT ALL ALS: Cohort description of a national ALS gene carrier study |
86 | Multimodal MRI to assess ALS progression over three to six months: Preliminary data from multicenter imaging study |
87 | Practice Parameters identified by Occupational Therapy Practitioners when working with persons with ALS: A Cross-Sectional Survey |
88 | Home-Based Neuromuscular Electrical Stimulation for Preservation of Function in Amyotrophic Lateral Sclerosis: Rationale and Study Design |
89 | The Nova-IMS: Concurrent Validity of Isometric Muscle Strength Testing Across Four Functional Domains and the ALSFRS-R Ceiling Effect in ALS |
90 | Evaluation of a Progressive Training Regimen to Extend ALS Patients' Functional Independence through Autonomous Wheelchair Control |
91 | Implementation and Analysis for Minimally Important Difference (MID) for the ALSFRS-R in the ASSESS ALL ALS study |
92 | The Rasch-Overall ALS Disability Scale (ROADS): Longitudinal Characteristics and Survival Predictions |
93 | Dynamic Weighting of External Factors Affecting Longitudinal ALSFRS-R Scores |
94 | A Harmonized Multisite Digital TDP-43 Pathology Resource Enables Automated Quantitative Analysis Across ALS and FTD |
95 | Performance of the Self-Reported ALS Functional Rating Scale-Revised in the ALL ALS Study |
96 | Towards restoring bimanual motor function for people with tetraplegia. |
97 | Association between dietary intake and blood glucose dynamics among C9orf72 ALS and asymptomatic gene-carriers |
98 | Correlation of Neurofilament Light-chain Levels and Body Composition with Survival in Amyotrophic Lateral Sclerosis |
99 | Comparison of Elective vs. Non-Elective Feeding Tube Placements Among Patients with ALS |
100 | Gastrointestinal symptoms pre and post feeding tube placement in people living with ALS |
101 | MIND Diet Adherence Is Associated with Reduced Circulating Inflammatory Biomarkers in ALS |
102 | Respiratory Care and Ventilation (RCV) Committee of the Network for Excellence in Amyotrophic Lateral Sclerosis (NEALS) Patient Care Status-Future Needs Assessment Surveys 2010-2024: Longitudinal Platform for Identifying GapsChallenges in USA ALS Care/Educational Opportunities to Deploy Best Practices |
104 | Correlation Between Subjective Respiratory Symptoms And Objective Respiratory Parameters In Patients With Amyotrophic Lateral Sclerosis: Experience From A Chilean Center |
105 | At-Home Telespirometry Identifies Baseline Erect Slow Vital Capacity (eSVC) at ≤80%-Predicted as a Pivotal Benchmark Separating Rapid From Less Rapid Decline in eSVC, Supine SVC and Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Score in Observational Study (NCT05106569) |
106 | Differential Respiratory Correlations in Amyotrophic Lateral Sclerosis: The Effect of Site of Onset on Clinical Markers |
107 | Development of a Multidisciplinary Motor Neuron Disease Clinic in Chile: A Seven-Year Experience |
109 | A Prompt-Engineered Large Language Model Pipeline to Improve ALS Referral Triage Efficiency - A Pilot Study |
110 | Bridging the Gap: Electronic Questionnaires to Enhance ALS Patient Engagement and Research Interest |
111 | The Rapid Access ALS Clinic Model: A Step Towards Addressing ALS Diagnostic Delay |
112 | Evaluating Leadership-Driven Workflow Redesign to Improve Referral Coordination in Multidisciplinary ALS Clinics |
113 | Evaluating the VA ALS System of Care: A Literature Review |
114 | Emergencies in a Multidisciplinary ALS Clinic Cohort: Massachusetts General Hospital Healey Center Experience |
115 | Streamlining ALS Clinic Operations with a Google Sheet-Based Tracking System |
116 | Measuring Clinician Satisfaction in a Newly Established Multidisciplinary ALS Clinic |
117 | Multidisciplinary Clinic Attendance and Patterns of Care in the U.S. National ALS Registry, 2013-2023 |
118 | Quality improvement in ALS multidisciplinary clinic: increased patient satisfaction after redesign |
119 | Navigating Complex Conversations-The Provider's Perspective |
120 | IMproving PAlliative Care Teamwork in ALS (IMPACT-ALS): Addressing Existential Distress Among ALS Care Partners |
121 | Longitudinal Progression of Depression in Amyotrophic Lateral Sclerosis Despite Similar Functional Decline: A Retrospective Cohort Study from a Multidisciplinary ALS Clinic |
122 | Implementing the Distress Thermometer in a multidisciplinary ALS clinic |
Anchor 1
Abstract #
Abstract Title
225 | The ALS Knowledge Portal: an open, federated data resource for ALS research |
226 | Connecting the Dots: Harmonizing Heterogeneous ALS/MND Data for Cross-Study Analysis and Collaborative AI Research |
227 | Neuromine: A Standardized, Collaborative ALS Data Ecosystem Driving Discovery |
228 | Characterizing Disease Progression in the Target ALS Global Natural History Study |
229 | The Vanderbilt ALS Research Center Biorepository: A Longitudinal Biospecimen Resource for ALS and Related Disorders |
230 | Multimodal Assessment of Speech, Respiratory, Orofacial and Limb Motor Function in ALS Patients: An Update from the Target ALS Global Natural History Study |
231 | One Disease, Many Presentations: Clinical Heterogeneity in the Target ALS Global Natural History Study |
232 | Subject-Level Reporting Using Supervised Automation in Longitudinal Observational Studies |
233 | Bridging Clinical and Molecular Insights in ALS: The Target ALS Postmortem Tissue Core and the Power of Paired Pre- and Postmortem Collections |
234 | Recovering Missing Item-Level ALSFRS-R Trajectories from Clinical Notes: Cross-Cohort Validation of a Calibrated AI Model - CLIO |
235 | Accounting for Route of Administration When Using PRO-ACT as External Controls in ALS Trials |
236 | From Data Sharing to Data Creation: Ethical Challenges and Governance of AI-Derived Participant Information in ALS/MND Research |
237 | Legal and Regulatory Framework for Data Sharing in ALS/MND |
239 | Advancing ALS Research Through Integrated Digital Infrastructure: Insights from the ALL ALS Program |
240 | Ankle-worn accelerometry provides candidate longitudinal gait endpoints for ALS clinical trials |
241 | Prescribed exercises offer a low-burden digital measure of lower limb function in ALS |
242 | Garmin Wearable Metrics as Digital Biomarkers of Functional and Respiratory Status in Amyotrophic Lateral Sclerosis |
POSTER SESSION 2: October 29 4:50-6:30 PM ET
Anchor 2
POSTER AWARDS
Basic Science Abstract Award
The Basic Science Abstract Award will be given to an outstanding abstract poster presentation focused on basic science.
Clinical Investigation Abstract Award
The Clinical Investigation Abstract Award will be given to an exceptional abstract poster presenter focused on clinical investigation.
UMN Achievement Award
The eigth annual UMN Achievement Award will be given to two abstracts focusing on PLS/UMN research. The UMN Achievement Award is supported by the Spastic Paraplegia Foundation (SPF) to promote UMN research and recognize those who contribute significantly to this field.
SCIENCE HIGHLIGHTS
Science Symposium Presentation
Up to 2 abstract submissions focusing on sporadic ALS will be selected for 10-minute presentations during the Science Symposium portion of our conference.
Lightening Science Talks
Up to 12 abstract submissions will be selected for 3-minute presentations during the conference.
bottom of page